Drug Approval | April 10, 2023
Virpax reports on progress of Envelta
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The increase of stake in Aster DM Healthcare is a reiteration of the confidence in the business across geographies
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
Subscribe To Our Newsletter & Stay Updated
